⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EYPT News
EyePoint Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
EYPT
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
globenewswire.com
EYPT
Form 8-K
sec.gov
EYPT
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
globenewswire.com
EYPT
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
globenewswire.com
EYPT
EyePoint Announces Participation at Upcoming Investor Conferences
globenewswire.com
EYPT
EyePoint Appoints Michael Campbell as Chief Commercial Officer
globenewswire.com
EYPT
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
EYPT
February is Age-related Macular Degeneration (AMD) and Low Vision Month at Prevent Blindness, Designed to Provide Helpful Sight-saving Resources and Support Programs
prnewswire.com
EYPT
AMGN